NEW GENESIS/MONTICELLO DRUG, LLC – Trademark Portfolio
Entity Type: 16
NEW GENESIS/MONTICELLO DRUG, LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 12 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include 666, HEET, and TRONOLANE. The owner is based in JACKSONVILLE, FL.
2801 LORIMIER TERRACE
JACKSONVILLE, FL 32207
Showing of trademarks Trademarks
Trademark Classifications
NEW GENESIS/MONTICELLO DRUG, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does NEW GENESIS/MONTICELLO DRUG, LLC have?
NEW GENESIS/MONTICELLO DRUG, LLC has 13 U.S. trademarks filed with the USPTO. Of these, 4 registered, 9 cancelled.
What trademark classes does NEW GENESIS/MONTICELLO DRUG, LLC file in?
NEW GENESIS/MONTICELLO DRUG, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are NEW GENESIS/MONTICELLO DRUG, LLC's most well-known trademarks?
NEW GENESIS/MONTICELLO DRUG, LLC's registered trademark portfolio includes well-known marks such as 666, HEET, and TRONOLANE. These are among 4 currently registered trademarks in the portfolio.
What is NEW GENESIS/MONTICELLO DRUG, LLC's trademark registration success rate?
NEW GENESIS/MONTICELLO DRUG, LLC has a 31% trademark registration rate, with 4 out of 13 resolved applications resulting in successful registration. Currently, 0 applications are pending review.